Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. Dec. 7, 2018. Diana Zuckerman.

Executive Summary

A research and patient advocacy organization was critical of the device industry's and US FDA's long-term post-market surveillance of breast implants as part of a recent study by the group of women who have had their implants removed. The preliminary results of a study released Nov. 26 by the National Center for Health Research pointed to an increase in symptoms of autoimmune and connective tissue disease among women who have had breast implants. See what Diana Zuckerman, the president for the National Center for Health Research, said about it here.

“Device registries are focused on counting the number of surgeries, rather than evaluating symptoms or other complications. The focus on surgeries and revision surgeries omits many of the outcomes that matter most to patients, and especially patients who may not have the financial resources to undergo additional surgeries.” – Diana Zuckerman, president, National Center for Health Research

Click here for a free trial of Medtech Insight





Related Content

Study Highlights Autoimmune, CTD Issues In Women Who Had Breast Implants





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts